Bright Peak Therapeutics rakes in $107m Series B

Bright Peak Therapeutics, a developer of cytokine immunotherapies to treat cancer and autoimmune disease, has raised $107 million in Series B financing.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this